ATH alterity therapeutics limited

11.1%

1.0¢

Ann: Trading Halt, page-147

First 147 Last

Share
Profile

Follow
Kyriaco

2,008 Posts.

830

06/02/25

20:05

Post #: 77743129
Share

Originally posted by amb005: ↑

I feel some of that frustration myself.

Most of us holding here were holding over the biggest risk, the outcome of phase 2 trials, if they were negative we would have all lost our shirts. They were positive and we are rewarded but with only a day of good price action, which was promptly sold into, and now knowing this cap raise was on the cards its makes a lot of sense why we were sold into.

The thing that is frustrating , is that now the sophs get to come in, they dont have to hold over trial risking their shirts like holders, they take no risk of bad trial results, and they get a price that we were trading at before these results were even released. Does rub me the wrong way. And dare I ask how many of these sophs are cozy with the board?

And then there’s the valuation—a paltry $100 million. Many of us were conservatively estimating this company at $200–300 million, higher even given the recent results, puzzled at why the price was trading so low (its been answereed now). Yet we’ve given 40% of the company to the sophs for a mere $40 million. By any sensible measure, 40% should command $100 million— so the $40 mill is a deep discount that hands the sophs the upside with none of the attendant risk holders had to face. Curious to see an updated top 20 when all is said and done.

Resolutions from this board are rubber stamped, so they do what they want and we just watch. There are positives though and credit where it’s due: they stuck to their word—no capital raise before results—and if it is infact true that this raise was oversubscribed means we’ve got a well-funded company. At this point, all we can do is hope management deploys that $40 million wisely Im hoping some of it goes to courting big pharma with enough vision to value these assets appropriately for the next deal.

Expand

that is exactly their plan !

as a larger holder I am very happy

oversubscribed 40m raise in a tough market is an outstanding result

and some huge US biotech funds/instos joining the register is a sensational vote of confidence

onwards & upwards !!

ATH Price at posting: 1.2¢ Sentiment: Buy Disclosure: Held
16 Upvote

0 Great analysis

Reply

Top Stories

'Not possible' to port renewable gas: ACCC takes AGN to court

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

First 147 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.0¢		Change 0.001(11.1%)		Mkt cap ! $91.27M

Open	High	Low	Value	Volume
0.9¢	1.0¢	0.9¢	$41.54K	4.357M

Buyers (Bids)

No.	Vol.	Price($)
35	11136808	0.9¢

Sellers (Offers)

Price($)	Vol.	No.
1.0¢	4729475	10

View Market Depth

No.	Vol.	Price($)
35	11136808	0.009
18	11245794	0.008
16	10257963	0.007
13	8003518	0.006
7	3350002	0.005

Price($)	Vol.	No.
0.010	4729475	10
0.011	5969414	15
0.012	24005905	30
0.013	6944325	13
0.014	12788180	6

Last trade - 16.10pm 27/06/2025 (20 minute delay)

ATH (ASX) Chart

Ann: Trading Halt, page-147

'Not possible' to port renewable gas: ACCC takes AGN to court

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Boss extends June win streak with boosted Alta Mesa extraction rates

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-147

Top Stories

'Not possible' to port renewable gas: ACCC takes AGN to court

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Boss extends June win streak with boosted Alta Mesa extraction rates

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News